Pro Medicus Limited shares soar on blockbuster outlook

Credit: Language translation

Small-cap healthcare and technology business Pro Medicus Limited (ASX: PME) saw its shares surge 5.5% today after announcing a $3 million five-year contract with a German hospital operator.

Founder led with overseas exposure and the tailwinds of being a digital healthcare business this small-cap Melbourne-based company looks to tick the boxes as an outstanding growth prospect.

The cloud-based software Pro Medicus provides helps healthcare operators to improve the storage, sharing and administration of patient records collected in the course of providing healthcare services.

Moreover, those electronic records and medical images are only likely to soar in volume over time due to new technologies and higher standards of care, which puts Pro Medicus and its software in something of a growth sweet spot.

On a roll

The company’s been winning big new contracts to prove the point and continues to grow in both private and public hospitals in the US and Europe.

The German contract win is for a public sector hospital and often once traction is gained within public healthcare sectors further success often materialises as a consequence of a market-leading reputation and the reversion to uniformity.

While public healthcare administrations globally have eye-wateringly huge budgets the private sector is also constantly looking to save costs and lift profit via the kind of technology that Pro Medicus provides.

Recently the business secured an $11 million deal over a five-year period with a private US healthcare operator in what is the world’s largest private healthcare market.


Unsurprisingly, the stock has tripled in value over the past year and the company now has a contracted revenue stream of more than $50 million over the next five years.

Based on recent share prices, Pro Medicus is now valued around $330 million with great expectations for further growth built into the price, which means any buyer at today’s prices would need to be especially bullish on the company’s outlook.

However, it remains that Pro Medicus has huge global healthcare markets to grow into with several tailwinds – the sky could really be the limit for this junior healthcare business.

Others operating in the healthcare and technology space worth a look include Somnomed Limited (ASX: SOM) and Primary Health Care Limited (ASX: PRY).

Although if you’re looking for some red hot income stocks it might be worth reading on below…

NEW! The Motley Fool's top dividend stock for 2015-2016

Handpicked by our investment experts, this promising ASX stock boasts a fully franked yield that puts term deposits to shame! You can get the name and code FREE in our brand-new report, "The Motley Fool's Top Dividend Stock for 2015." Click here now for your free copy.

Motley Fool contributor Tom Richardson has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.